Clofarabine induces ERK/MSK/CREB activation through inhibiting CD99 on Ewing sarcoma cells.
Clofarabine, an FDA approved purine analog, is used in the treatment of relapsed or refractory acute lymphoblastic leukemia. Clofarabine acts by inhibiting DNA synthesis. We demonstrated that clofarabine may have a novel function though inhibiting CD99, a transmembrane protein highly expressed on Ew...
Main Authors: | Handan Sevim, Haydar Çelik, Levent Düşünceli, Ceyda S Ceyhan, Anna Molotkova, Kay Nakazawa, Garrett T Graham, Jeffrey R Petro, Jeffrey A Toretsky, Aykut Üren |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0253170 |
Similar Items
-
Use of clofarabine for acute childhood leukemia
by: A Pession, et al.
Published: (2010-06-01) -
Clofarabine desensitization: A case report
by: Sarah M. Hayes, et al.
Published: (2017-01-01) -
Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature
by: Alison O'Neill, et al.
Published: (2013-01-01) -
Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters
by: Siennah R. Miller, et al.
Published: (2021-08-01) -
Older Adult Use and Outcomes in a Digital Musculoskeletal (MSK) Program, by Generation
by: Grace Wang, et al.
Published: (2021-08-01)